Институциональные инвесторы увеличили позиции в биотехнологической компании Annexon

J. Goldman & Co LP purchased a new stake in Annexon, Inc. (NASDAQ:ANNX – Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 116,046 shares of the company’s stock, valued at approximately $663,000. J. Goldman & Co LP owned approximately 0.06% of Annexon at the end of the most recent reporting period. A number of other institutional investors have also modified their holdings of the stock. Mirae Asset Global Investments Co. Ltd. increased its holdings in Annexon by 65.6% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,033 shares of the company’s stock valued at $35,000 after buying an additional 2,785 shares during the last quarter. Landscape Capital Management L.L.C. acquired a new position in Annexon in the fourth quarter worth $50,000. CIBC Bancorp USA Inc. bought a new stake in shares of Annexon during the 3rd quarter valued at about $31,000. Mercer Global Advisors Inc. ADV bought a new position in shares of Annexon during the fourth quarter valued at approximately $52,000. Finally, Abel Hall LLC bought a new position in Annexon during the 1st quarter worth $61,000. Wall Street Analyst Weigh In A number of brokerages recently weighed in on ANNX. Cantor Fitzgerald restated an “overweight” rating on shares of Annexon in a research note on Monday, July 13th. Citizens Jmp raised Annexon from an “underperform” rating to a “market perform” rating in a research note on Thursday, August 13th. Needham & Company LLC lifted their target price on Annexon from $11.00 to $25.00 and gave the stock a “buy” rating in a report on Wednesday, July 15th. Citigroup assumed coverage on Annexon in a report on Tuesday, July 21st. They issued a “market underperform” rating on the stock. Finally, The Goldman Sachs Group initiated coverage on Annexon in a report on Tuesday, May 12th. They set a “neutral” rating and a $7.00 target price for the company. Five investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $15.33. Annexon Price Performance Annexon stock opened at $4.99 on Thursday. Annexon, Inc. has a fifty-two week low of $2.03 and a fifty-two week high of $7.18. The firm’s 50 day simple moving average is $5.40 and its 200-day simple moving average is $5.44. The company has a market cap of $946.00 million, a P/E ratio of -4.30 and a beta of 1.18. Annexon (NASDAQ:ANNX – Get Free Report) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.04). On average, analysts expect that Annexon, Inc. will post -1.01 EPS for the current fiscal year. Annexon Profile Annexon Inc is a clinical-stage biotechnology company focused on the discovery and development of complement-targeted therapies for patients with neurodegenerative and neuroimmune diseases. The company’s research platform centers on the inhibition of the C1 complex, a key initiator of the classical complement pathway implicated in several rare and life-threatening disorders. By selectively targeting upstream complement activation, Annexon aims to prevent the aberrant immune-mediated damage that characterizes conditions such as Guillain-Barré syndrome (GBS) and autoimmune neuropathies. At the core of Annexon’s pipeline is ANX005, a humanized monoclonal antibody directed against the C1q subcomponent, currently in Phase 2 clinical trials for acute GBS and chronic neurodegenerative indications. See Also Want to see what other hedge funds are holding ANNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Annexon, Inc. (NASDAQ:ANNX – Free Report). Receive News & Ratings for Annexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Annexon and related companies with MarketBeat.com's FREE daily email newsletter.